Alessandro Poli, Stefano Ratti, Carlo Finelli, Sara Mongiorgi, Cristina Clissa, Annalisa Lonetti, Alessandra Cappellini, Alessia Catozzi, Marilena Barraco, Pann-Ghill Suh, Lucia Manzoli, James A McCubrey, Lucio Cocco, Matilde Y Follo
PI-PLCβ1 is involved in cell proliferation, differentiation, and myelodysplastic syndrome (MDS) pathogenesis. Moreover, the increased activity of PI-PLCβ1 reduces the expression of PKC-α, which, in turn, delays the cell proliferation and is linked to erythropoiesis. Lenalidomide is currently used in low-risk patients with MDS and del(5q), where it can suppress the del(5q) clone and restore normal erythropoiesis. In this study, we analyzed the effect of lenalidomide on 16 patients with low-risk del(5q) MDS, as well as del(5q) and non-del(5q) hematopoietic cell lines, mainly focusing on erythropoiesis, cell cycle, and PI-PLCβ1/PKC-α signaling...
February 2018: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology